Marine organisms as a source of new anticancer agents

Lancet Oncology

Volumn 2, Issue 4, 2001, Pages 221-225

  Schwartsmann, Gilberto ^a,b   Da Rocha, Adriana Brondani ^b   Berlinck, Roberto G S ^c   Jimeno, Jose ^d  

^a S Amer Off Anticancer Drug D   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

^d PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN 1; LACTONE; MACROLIDE;

ANIMAL; CLINICAL TRIAL; DRUG SCREENING; FORECASTING; HUMAN; NEOPLASM; REVIEW; UROCHORDATA;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; FORECASTING; HUMANS; LACTONES; MACROLIDES; NEOPLASMS; UROCHORDATA;

EID: 0039923005     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00292-8     Document Type: Review

References (58)

1. Mans D.R.A., Rocha A.B., Schwartsmann G. Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. Oncologist. 5:2000;185-198.
2. Cragg G.M., Newman D.J., Snader K.M., et al. Natural products in drug discovery and development. J Nat Prod. 60:1997;52-60.
3. Schwartsmann G., Workmann P. Anticancer drug screening and discovery in the : a European perspective. Eur J Cancer ; 29. 1993:1990s;3-14.
4. Schwartsmann G. Marine organisms and other novel natural sources of new cancer drugs. Ann Oncol. 11:2000;235-243.
5. Cragg G.M., Newman D.J. Discovery and development of antineoplastic agents from natural sources. Cancer Invest. 17:1999;153-163.
6. Cragg G.M., Newman D.J., Weiss R.B. Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents. Semin Oncol. 24:1997;156-163.
7. Pomponi A.S. The bioprocess-technological potential of the sea. J Biotechnol. 70:1999;5-13.
8. Schweitzer J., Handley F.G., Edwards J., et al. Summary of the workshop on drug development, biologic diversity, and economic growth. J Natl Cancer Inst. 83:1991;1294-1298.
9. Rinehart K.L. Antitumor compounds from tunicates. Med Res Rev. 20:2000;1-27.
10. Geldof A.A., Mastbergen S.C., Henrar R.E.C., Faircloth G.T. Cytotoxicity and neurocytoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother Pharmacol. 44:1999;312-318.
11. Shin D.M., Holoye P.Y., Murphy W.K., et al. Phase I/II clinical trial of didemnin B in non-small cell lung cancer: neuromuscular toxicity is dose-limiting. Cancer Chemother Pharmacol. 29:1991;145-149.
12. Weiss R.B., Peterson B.L., Allen S.L., et al. A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study. Invest New Drugs. 12:1994;41-43.
13. Urdiales J.L., Morata P., Nunez de Castro I., Sanchez-Jimenez F. Antiproliferative effect of dehydrodidemin B (DDB), a depsipeptide isolated from Mediterraneam tunicates. Cancer Lett. 102:1996;31-37.
14. Raymond E., Ady-Vago N., Ribrag V., et al. Phase I and pharmacokinetic study of aplydine, a marine derived compound, given as a 24h infusion every 2 weeks in patients with advanced solid tumors and non-Hodgkin's lymphoma. Ann Oncol. 11:2000;134.
15. Izquierdo M.A., Bowman A., Martinez M., et al. A phase I study of aplidine, a marine derived compound, given as a 1h infusion weekly X 3 in advanced solid tumors and non-Hodgkin's lymphomas. Ann Oncol. 11:2000;134.
16. Maroun J., Belanger K., Seymour L., et al. Phase I study of aplidine in a 1 hour daily infusion X 5 q 3 weeks in patients with solid tumors and low and intermediate grade non-Hodgkin's lymphomas: A National Cancer Institute of Canada-Clinical Trials Group study. Ann Oncol. 11:2000;136.
17. Garcia-Rocha M., Garcia-Gravalos M.D., Avila J. Characterisation of antimitotic products from marine organisms that disorganize the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15. Br J Cancer. 73:1996;875-883.
18. Zewails-Foote M., Hurley L.H. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem. 42:1999;2493-2497.
19. Minuzzo M., Marchini S., Broggini M., et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA. 12:2000;6780-6784.
20. Demetri G, Garcia-Carbonero, Harmon D, et al. Ecteinascidin-743 (ET-743) induces objective responses and disease control in patients with advanced non-osseous sarcomas: results from phase II trials. Ann Oncol 2000; 11: 126.
21. Le Cesne A., Judson I., Radford J., et al. Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: a STBSG-EORTC trial. Ann Oncol. 11:2000;126.
22. Demetri G., Seiden M., Garcia Carbonero R., et al. Ecteinascidin (ET-743) shows promising activity in distinct populations of sarcoma patients: summary of 3 US-based phase II trials (Abstr 2177). Proc Am Soc Clin Oncol. 19:2000;2177.
23. Le Cesne A., Judson I., Radford J., et al. Phase II study of ET-743 in advanced soft tissue sarcoma (ASTS) in adult: A STBSGEORTC trial (Abstr). Proc Eur Soc Med Oncol. 126:2000;5740.
24. Zelek L., Yovine A., Brain E., et al. Preliminary results of phase II study of Ecteinascidin-743 (ET-743) with the 24 hour (H) continuous infusion (CI) Q3weeks schedule in pretreated advanced/metastatic breast cancer (A/MBC) patients (Pts). Proceedings of the NCI-EORTC-AACR conference. Amsterdam, November 7-10, 2000: 85 (Abstr 212).
25. Zelek L., Yovine A., Brain E., et al. Preliminary results of phase II study of Ecteinascidin-743 (ET-743) with the 24 hour (H) continuous infusion (CI) Q3weeks schedule in pretreated advanced/metastatic breast cancer (A/MBC) patients (Pts). Proceedings of the NCI-EORTC-AACR conference. Amsterdam, November 7-10, 2000: 85 (Abstr 212).
26. Delaloge S., Yovine A., Taamma A., et al. Ecteinascidin-743: a marine derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol. 19:2001;1248-1255.
27. Poncet J. The dolastatins, a family of promising antineoplastic agents. Curr Pharm Des. 5:1999;139-162.
28. Bai R., Pettit G.R., Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol. 39:1990;1941-1949.
29. Pathak S., et al. Dolastatin-10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line. Oncol Rep. 5:1998;373-376.
30. Wright J.J., Blatner G., Cheson B.D. Clinical trials referral resource. Clinical trials of dolastatin-10. Oncology. 3:1999;68-70.
31. Pitot H.C., McElroy E.A., Reid J.M., et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 5:1999;525-531.
32. Madden T., Tran H.T., Beck D., et al. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 6:2000;1293-1301.
33. Krug L.M., Miller V.A., Kalemkerian G.P., et al. Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Ann Oncol. 11:2000;227-228.
34. Wender P.A., Hinkle K.W., Koehler M.F., Lippa B. The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues. Med Res Rev. 19:1999;388-407.
35. Pettit G.R., et al. Isolation and structure of bryostatin-1. J Am Chem Soc. 104:1982;6846-6848.
36. Trenn G., et al. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins. J Immunol. 140:1988;433-439.
37. Hornung R.L., et al. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro and in vivo activity. Cancer Res. 52:1992;101-107.
38. Varterasian M.L., et al. Phase I study of bryostatin-1 in patients with relapsed non-Hodgkin′s lymphoma and chronic lymphocytic leukemia. J Clin Oncol. 16:1998;56-62.
39. Jayson G.C., et al. A phase I trial of bryostatin 1 in patients with advanced malignancies using a 24 hour intravenous infusion. Br J Cancer. 72:1995;461-468.
40. Prendiville J., et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer. 68:1993;418-424.
41. Propper D.J., Macaulay V., Obyrne K.J., et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer. 78:1998;1337-1341.
42. Ahmad I., Al-Katib A.M., Beck F.W., Mohammad R.M. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenoside: case report. Clin Cancer Res. 6:2000;1328-1332.
43. Moore R.E. Cyclic peptides and depsipeptides from cyanobacteria: a review. J Ind Microbiol. 16:1996;134-143.
44. Ueda H., et al. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968 on Ha-ras transformed NIH3T3 cells. Biosci Biotech Biochem. 58:1994;1579-1583.
45. Nakajima H., et al. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res. 241:1998;126-133.
46. Ueda H., et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo). 47:1994;315-323.
47. Kowalsky R.J., et al. The microtubule-stabilising agent discodermolide competitively inhibits the binding of paclitaxel to tubulin polymers, enhances tubuline nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol. 52:1997;613-622.
48. ten Harr E., et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochem. 35:1996;243-250.
49. Kitagawa I., Kobayashi M. Antitumor marine natural products. Gan To Kagaku Ryoho. 17:1990;322-329.
50. Berlinck R.G.S., et al. Granulatimide, isogranulatimide and didemnimide E, aromatic alkaloids isolated from the Brazilian ascidian didemnum granulatum: structure elucidation, synthesis and G2 checkpoint inhibition activity. J Org Chem. 63:1998;9850-9856.
51. Casapullo A., Bifulco G., Bruno I., Riccio R. New bisindole alkaloids of the topsentin and hamacanthin classes from the Mediterranean marine sponge Rhaphisia lacazei. J Nat Prod. 63:2000;447-451.
52. Chen C.Y., Shen Y.C., Chen Y.J., et al. Bioactive sesquiterpenes from a Taiwanese marine sponge Parahigginsia sp. J Nat Prod. 62:1999;573-576.
53. Matsumoto S.S., Aughey H.M., Schmehl D.M., et al. Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction. Anticancer Drugs. 10:1999;39-45.
54. Rein K.S., Borrone J. Polyketides from dinoflagellates: origins, pharmacology and biosynthesis. Comp Biochem Physiol B Biochem Mol Biol. 124:1999;117-131.
55. McDaniel R., et al. Rational design of aromatic polyketide natural products by recombinant assembly of enzymatic units. Nature. 375:1995;549-554.
56. Kan Y., Fujita T., Sakamoto B., et al. A new cyclic depsipeptide from the hawaiian green alga bryopsis species. J Nat Prod. 62:1999;1169-1172.
57. Menon K., Alvarez E., Forler P., et al. Antitumor activity of cryptophycins: effect of infusion time and combination studies. Cancer Chemother Pharmacol. 46:2000;142-149.
58. Christian M.C., Pluda J.M., Ho T.C., et al. Promising new agents under development by the Division of Cancer Treatment, Diagnosis and Centers of the National Cancer Institute. Semin Oncol. 24:1997;219-240.